Roseburia intestinalis inhibits oncostatin M and maintains tight junction integrity in a murine model of acute experimental colitis

References

• Kamm MA. Rapid changes in epidemiology of inflammatory bowel disease. Lancet. 2017;390:2741–2742.
   PubMed Web of Science ®Google Scholar
• Hirano A, Umeno J, Okamoto Y, et al. Comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis. J Gastroenterol Hepatol. 2018;33:1590–1597.
   Web of Science ®Google Scholar
• Pascal V, Pozuelo M, Borruel N, et al. A microbial signature for Crohn's disease. Gut. 2017;66:813–822.
   PubMed Web of Science ®Google Scholar
• Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–1283.
   PubMed Web of Science ®Google Scholar
• Imhann F, Vich Vila A, Bonder M, et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut. 2018;67:108–119.
   PubMed Web of Science ®Google Scholar
• Duncan SH, Hold GL, Barcenilla A, et al. Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int J Syst Evol Microbiol. 2002;52:1615–1620.
   PubMed Web of Science ®Google Scholar
• Shen Z, Zhu C, Quan Y, et al. Insights into Roseburia intestinalis which alleviates experimental colitis pathology by inducing anti-inflammatory responses. J Gastroenterol Hepatol. 2018;33(10):1751–1760.
   Web of Science ®Google Scholar
• Zhu C, Song K, Shen Z, et al. Roseburia intestinalis inhibits interleukin17 excretion and promotes regulatory T cells differentiation in colitis. Mol Med Rep. 2018;17:7567–7574.
   PubMed Web of Science ®Google Scholar
• Chelakkot C, Ghim J, Ryu S. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50:103.
   PubMed Web of Science ®Google Scholar
• Holmberg FEO, Pedersen J, Jørgensen P, et al. Intestinal barrier integrity and inflammatory bowel disease: stem cell-based approaches to regenerate the barrier. J Tissue Eng Regen Med. 2018;12:923–935.
   PubMed Web of Science ®Google Scholar
• Li H, Gong Y, Xie Y, et al. Clostridium butyricum protects the epithelial barrier by maintaining tight junction protein expression and regulating microflora in a murine model of dextran sodium sulfate-induced colitis. Scand J Gastroenterol. 2018;53(9):1031–1042.
   PubMed Web of Science ®Google Scholar
• Simeoli R, Mattace Raso G, Lama A, et al. Preventive and therapeutic effects of Lactobacillus paracasei B21060-based synbiotic treatment on gut inflammation and barrier integrity in colitic mice. J Nutr. 2015;145:1202–1210.
   PubMed Web of Science ®Google Scholar
• Bron P, Kleerebezem M, Brummer R, et al. Can probiotics modulate human disease by impacting intestinal barrier function? Br J Nutr. 2017;117:93–107.
   PubMed Web of Science ®Google Scholar
• Hermanns H. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 2015;26:545–558.
   PubMed Web of Science ®Google Scholar
• West NR, Owens BMJ, Hegazy AN. The oncostatin M-stromal cell axis in health and disease. Scand J Immunol. 2018;88:e12694.
   PubMed Web of Science ®Google Scholar
• West N, Hegazy A, Owens B, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23:579–589.
   PubMed Web of Science ®Google Scholar
• Kolho K-L, Korpela K, Jaakkola T, et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol. 2015;110:921.
   PubMed Web of Science ®Google Scholar
• Magnusson MK, Strid H, Sapnara M, et al. Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J Crohns Colitis. 2016;10:943–952.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xu Z, He Y, et al. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems. 2018;3(1):e00188–17.
   PubMed Web of Science ®Google Scholar
• Neurath M. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269–278.
   PubMed Web of Science ®Google Scholar
• Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38:127–142.
   PubMed Web of Science ®Google Scholar
• Wirtz S, Popp V, Kindermann M, et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12:1295.
   PubMed Web of Science ®Google Scholar
• Na YR, Hong JH, Lee MY, et al. Proteomic analysis reveals distinct metabolic differences between granulocyte-macrophage colony stimulating factor (GM-CSF) and macrophage colony stimulating factor (M-CSF) grown macrophages derived from murine bone marrow cells. Mol Cell Proteomics. 2015;14:2722.
   PubMed Web of Science ®Google Scholar
• Mukai K, Miyagi T, Nishio K, et al. S100A8 production in CXCR2-expressing CD11b + Gr-1 high cells aggravates hepatitis in mice fed a high-fat and high-cholesterol diet. J Immunol. 2016;196:395–406.
   PubMed Web of Science ®Google Scholar
• Pothoven K, Norton J, Hulse K, et al. Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease. J Allergy Clin Immunol. 2015;136:737–746.e4.
   PubMed Web of Science ®Google Scholar
• Takata F, Sumi N, Nishioku T, et al. Oncostatin M induces functional and structural impairment of blood-brain barriers comprised of rat brain capillary endothelial cells. Neurosci Lett. 2008;441:163–166.
   PubMed Web of Science ®Google Scholar
• Pothoven K, Schleimer R. The barrier hypothesis and Oncostatin M: restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease. Tissue Barriers. 2017;5:e1341367.
   PubMed Web of Science ®Google Scholar
• de Souza H, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:739–749.
   PubMed Web of Science ®Google Scholar
• Gren S, Grip O. Role of monocytes and intestinal macrophages in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2016;22:1992–1998.
   PubMed Web of Science ®Google Scholar
• Hidalgo-Garcia L, Galvez J, Rodriguez-Cabezas M, et al. Can a conversation between mesenchymal stromal cells and macrophages solve the crisis in the inflamed intestine? Front Pharmacol. 2018;9:179.
   PubMed Web of Science ®Google Scholar
• Kühl AA, Erben U, Kredel LI, et al. Diversity of intestinal macrophages in inflammatory bowel diseases. Front Immunol. 2015;6:613.
   PubMed Web of Science ®Google Scholar
• Beigel F, Friedrich M, Probst C, et al. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members. PLoS One. 2014;9:e93498.
   PubMed Web of Science ®Google Scholar